CellaVision's new analyzer CellaVision® DM1200 presented at AACC in
the USA>
CellaVision's new analyzer CellaVision® DM1200 presented at AACC in the USA
(Thomson Reuters ONE) - CellaVision AB (publ), which develops and sells digital morphologyproducts for the routine analysis of blood and other body fluids,presents their new analyzer CellaVision® DM1200 at the internationallab exposition AACC Annual Meeting & Clinical Lab Expo in Chicago,USA, on July 19-23. The product is commercially available in Europeand will be available in North America and Japan when CellaVision hasreceived clearance from the respective countries' authorities."We see a substantial potential for this product on the European andNorth American markets as trends indicate that not only the large butalso the medium-sized laboratories aim to streamline their analyticalflow," says Yvonne Mårtensson, CEO of CellaVision. "This analyzer ispowerful and flexible, and is intended to serve as a platform forfuture applications, giving CellaVision yet more of a competitiveedge."The CellaVision DM1200 replaces manual microscopy for analysis ofblood samples and is aimed at clinical chemistry laboratories wishingto automate their manual differentials, making their analytical flowmore efficient. The hardware is prepared for body fluid analysis.The blood application is included in the CellaVision DM1200 and willbe commercially available in Europe by the end of July. Theapplication for body fluids is sold as a separate product and isintended to be released by the end of the year. The company isplanning to apply for product registrations in Canada, the US andJapan.CellaVision's current range of products includes the analyzersCellaVision® DM96 and CellaVision® DM8 as well as software for remoteaccess, and proficiency testing and education - CellaVision® RemoteReview Software and CellaVision® Competency Software. All of theproducts are compatible with each other and can be part of the samehospital network.CellaVision DM1200 will be presented at the AACC in Chicago, USA, onthe 19-23 of July 2009 in CellaVision's and Sysmex Amercia's showcases (238 and 2025 respectively). The convention is expected to draw20,000 international visitors. For more details, please visitwww.aacc.org.For more product information and a product picture, please seebelow.For more information, please contact:Yvonne Mårtensson, CEO, CellaVision ABPhone: +46 708 33 77 82. E-mail: yvonne.martensson(at)cellavision.comAbout CellaVisionCellaVision AB develops, markets, and sells market leading imageanalysis based systems for routine analysis of blood and other bodyfluids. The company has a core competence in development of softwareand hardware for automatic image analysis of cells and cell changesfor applications in health and medical care. The company develops andmarkets systems for automatic differentials of white blood cells andred morphology, and software for education and quality assurance ofdifferentials. The company's associates have expertise in advancedimaging analysis, artificial intelligence, and automated microscopy.The company headquarters are in Lund, Sweden. The company also hassubsidiaries in Florida, USA, Toronto, Canada and Yokohama, Japan.For more information, visit www.cellavision.com.CellaVision's share is listed on First North Premier at the OMXStockholm Stock Exchange. CellaVision is traded under the tickersymbol CEVI and the ISIN code SE0000683484. The company's CertifiedAdvisor is Remium AB.Features and Benefits - CellaVision® DM1200CellaVision DM1200 automates the work that is traditionally done bylaboratory personnel using microscopes. The analyzer performs apreliminary WBC Differential and RBC Characterization, and providesfunctionality for platelet estimation. Using technology for digitalimage analysis, cells in blood can be classified automatically, whichallows for both time reductions and more standardized analyses. TheMedical Technologist performs the final verification on his or hercomputer screen. After signing off the result, it is automaticallysent to the laboratory data system (LIS), where it is archivedtogether with the patient record. The digital form of the analysisresult provides other benefits, such as traceability and the abilityto share results with colleagues within or outside the hospital,which increases sharing of expertise between units and makes themmore productive and cost-effective.CellaVision DM1200 is used after the cell counter has analyzed thesample and is compatible with all other CellaVision products. It caneasily be a part of any hematology workflow.Features* Analysis of Peripheral Blood* Prepared for Body Fluids* Allows Digital Slides creation. Primarily for hematology smears, but also applicable to other types of specimens, such as Pathology, Cytology and Bone Marrow for research and educational purposes.* Automated workflow - walk away* Sample identification through barcode scanning and LIS query* Automatic immersion oil dispensing* Identification of the optimal analysis area* WBC Differential* RBC Characterization* Pre-classification of blood cells into 18 classes (WBCs: 12, Non-WBCs: 6)* Functionality for platelet estimation (PLT)* Loading capacity: 12 slides* Throughput: 20 slides/h (peripheral blood)* Slide preparation methods (wedged): Automated slide maker and stainers or manual methods. Slides with clipped/round corners.* Digital archiving of cell images and results together with the patient record.http://hugin.info/132164/R/1329154/313667.tifThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
" alt="ITCL - Extension of Charter>">
" alt="Reminder: Nordea's result for the second quarter 2009 will be
presented on Tuesday 21 July 2009>">
Datum: 16.07.2009 - 09:08 Uhr
Sprache: Deutsch
News-ID 3633
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 559 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CellaVision's new analyzer CellaVision® DM1200 presented at AACC in
the USA>"
steht unter der journalistisch-redaktionellen Verantwortung von
CellaVision AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
